Selected stock price target news of the day - April 1st, 2025

By: Matthew Otto

Cabaletta Bio Posts Losses in Q4 2024 as R&D Spending Rises, Clinical Trials Progress

Cabaletta Bio is preparing for an FDA meeting in the first half of 2025 to discuss registrational trial designs for rese-cel in myositis, a disease affecting approximately 70,000 people in the U.S. Since November 2024, Cabaletta has maintained an enrollment rate of about one patient per week in the RESET™ clinical development program, with 33 patients enrolled across 56 active clinical trial sites in the U.S. and Europe as of March 14, 2025. The program is targeting multiple autoimmune diseases, including systemic sclerosis (SSc), which affects around 100,000 people in the U.S.; systemic lupus erythematosus (SLE), impacting about 200,000 individuals in the U.S.; and generalized myasthenia gravis (gMG), which affects around 60,000 people in the U.S.

Financially, Cabaletta ended 2024 with $164.0 million in cash and cash equivalents, funding operations into the first half of 2026. Research and development expenses for Q4 2024 rose to $25.5 million from $17.4 million in Q4 2023. Full-year R&D spending increasing to $97.2 million from $55.4 million in 2023. General and administrative expenses for Q4 2024 were $8.3 million, up from $5.7 million in Q4 2023. Full-year expenses reached $27.9 million compared to $19.2 million in 2023.

Cabaletta reported a net loss of $32.6 million for Q4 2024 and $115.9 million for the full year. Compared to losses of $20.9 million and $67.7 million in the respective periods of 2023. With ongoing clinical trials and expanded manufacturing partnerships, Cabaletta is positioning rese-cel as a potential treatment for a subset of the estimated 430,000 individuals affected by the targeted autoimmune diseases in the U.S. alone.

Analysts Adjust Price Targets Amid Developments

Morgan Stanley analyst Michael Ulz maintained an Overweight rating yet lowered the price target from $30 to $22.
HC Wainwright & Co. analyst Douglas Tsao reiterated a Buy rating and the price target at $25.
UBS analyst Trung Huynh cut the price target to $7.

Which Analyst has the best track record to show on CABA?

Analyst Derek Archila (WELLS FARGO) currently has the highest performing score on CABA with 3/6 (50%) price target fulfillment ratio. His price targets carry an average of $3.69 (159.74%) potential upside. Cabaletta Bio stock price reaches these price targets on average within 319 days.

Celcuity Reports Q4 2024 Financial Results and Clinical Trial Updates

Celcuity ended Q4 2024 with approximately $235.1 million in cash, cash equivalents, and short-term investments, expected to fund clinical development activities through 2026. Total operating expenses rose to $36.4 million in Q4 2024, compared to $19.7 million in Q4 2023, driven primarily by a $15.4 million increase in R&D expenses, which totaled $33.5 million for the quarter. General and administrative expenses were $3.0 million, up from $1.6 million in the prior-year period.

Celcuity reported a net loss of $36.7 million, or $0.85 per share, compared to $18.8 million, or $0.65 per share, in Q4 2023. On a non-GAAP basis, adjusted net loss was $32.3 million, or $0.75 per share, which was $0.04 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $0, in line with consensus expectations.

Celcuity remains on track with its clinical development programs, which target HR+, HER2- advanced breast cancer—a condition affecting approximately 300,000 new patients annually in the U.S. alone. Of these, around 70% have hormone receptor-positive (HR+), HER2-negative (HER2-) subtypes, the primary focus of Celcuity’s VIKTORIA trials.

The VIKTORIA-1 Phase 3 trial is set to report topline data for the PIK3CA wild-type cohort in Q2 2025, with results for the PIK3CA mutant-type cohort expected in Q4 2025. The VIKTORIA-2 Phase 3 trial is on schedule to enroll its first patient in Q2 2025, with plans to recruit approximately 638 participants across multiple global sites. Additionally, the Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer (mCRPC), which affects over 40,000 men in the U.S. annually, is expected to report preliminary data in late Q2 2025.

Analysts Reaffirm Buy Ratings as Clinical Milestones Approach

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating and a $27 price target.
Needham analyst Gil Blum reaffirmed a Buy rating and a $29 price target.
Stifel analyst Bradley Canino reiterated a Buy rating and a price target of $42.

Which Analyst has the best track record to show on CELC?

Analyst Alexander Nowak (CRAIG HALLUM) currently has the highest performing score on CELC with 3/5 (60%) price target fulfillment ratio. His price targets carry an average of $9.34 (52.89%) potential upside. Celcuity stock price reaches these price targets on average within 271 days.

PVH Reports 2024 Results and Announces 2025 Share Repurchase Plan

PVH reported a 5% decrease in fourth-quarter revenue, totaling $2.372 billion, compared to $2.490 billion in the prior year. On a constant currency basis, revenue declined 2%. It exceeded its earlier revenue guidance, which projected a 6-7% decrease. The fourth-quarter operating margin stood at 8.9%, falling short of the 9.2% guidance due to a $28 million actuarial loss on retirement plans. Earnings per share (EPS) for Q4 were $3.27, surpassing the analyst estimate of $3.24.

For the full year, PVH’s revenue decreased 6% to $8.653 billion, while EPS amounted to $10.56, slightly under the previous year’s result of $10.76. Despite these declines, PVH achieved a 120 basis point improvement in gross margin for the year, driven by a favorable shift in channel mix and cost efficiencies. Fourth-quarter revenue of $2.37 billion also exceeded the consensus estimate of $2.34 billion.

Looking ahead to 2025, PVH forecasts a full-year EPS range of $12.40 to $12.75, above the consensus estimate of $11.68. For Q1 2026, PVH expects EPS between $2.10 and $2.25, slightly below the consensus estimate of $2.24.

PVH also plans to repurchase $500 million of its stock in 2025 through accelerated share repurchase agreements. This follows the completion of a similar repurchase program in 2024, where it bought back 4.7 million shares for approximately $500 million. The outlook for 2025 includes an increase in interest expenses, projected at $85 million, and a tax rate of around 22%.

Analyst Ratings and Price Target Adjustments Following Q4 Results

BMO Capital analyst Simeon Siegel maintained a Market Perform rating and lowered the price target from $106 to $93.
Telsey Advisory Group analyst Dana Telsey kept an Outperform rating and a $90 price target.
JPMorgan analyst Matthew Boss lowered the price target to $91.
Evercore ISI analyst Michael Binetti reduced the price target from $139 to $105.

Which Analyst has the best track record to show on PVH?

Analyst Paul Lejuez (CITI) currently has the highest performing score on PVH with 15/16 (93.75%) price target fulfillment ratio. His price targets carry an average of $5.22 (7.82%) potential upside. PVH stock price reaches these price targets on average within 161 days.